boulardii offers rapid relief
TRANSCEND-T2D-1 reported results on March 19, 2026 the first Phase 3 diabetes readout: These trials are expected to further broaden retatrutide's potential label across metabolic, musculoskeletal, and liver disease indications
Impact of semaglutide on inflammatory markers in gout patients: A randomized controlled trial
Obesity (Silver Spring) 18 , 773779 (2010)
The Health Not Hype campaign will deliver evidence-based information to patients, caregivers, clinicians, and community leaders through a national communications initiative led by NMQFs Center for Communications and Public Affairs and the ForYourHealth.News platform
Reactive oxygen species (ROS)-induced ROS release: a new phenomenon accompanying induction of the mitochondrial permeability transition in cardiac myocytes